Low-dose carbon monoxide may explain the paradoxical reduced risk of Parkinson’s disease among smokers
Researchers found that treating lab models of PD with low doses of carbon monoxide—comparable to the exposure experienced by people who smoke—protected against neurodegeneration and prevented the accumulation of a key disease-related protein